Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

CGM097

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Novartis

Drug class:

MDM2 inhibitor

Related drugs:

ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	palbociclib + CGM097 Sensitive: D – Preclinical palbociclib + CGM097 Sensitive : D	palbociclib + CGM097 Sensitive: D – Preclinical palbociclib + CGM097 Sensitive : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	CGM097 Sensitive: D – Preclinical CGM097 Sensitive : D	CGM097 Sensitive: D – Preclinical CGM097 Sensitive : D
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	AEB071 + CGM097 Sensitive: D – Preclinical AEB071 + CGM097 Sensitive : D	AEB071 + CGM097 Sensitive: D – Preclinical AEB071 + CGM097 Sensitive : D
GNA11 mutation	Uveal Melanoma	GNA11 mutation	Uveal Melanoma	AEB071 + CGM097 Sensitive: D – Preclinical AEB071 + CGM097 Sensitive : D	AEB071 + CGM097 Sensitive: D – Preclinical AEB071 + CGM097 Sensitive : D